DHODH and pleural mesothelioma: Further analysis of the drug sensitivity of Leflunomide, an FDA-approved agent targeting DHODH, revealed a positive correlation between NF2 protein levels and drug sensitivity typically existed in pleural mesothelioma across pan-cancer cell lines, indicating that this association might be tissue context-specific (Fig. EV4N,O; Table EV3).